JAGUAR HEALTH, INC. Comprehensive Income
JAGUAR HEALTH, INC. (JAGX) reported Comprehensive Income of -$12.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-19
- JAGUAR HEALTH, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$12.70M.
- JAGUAR HEALTH, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$7.42M.
- JAGUAR HEALTH, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$23.20M.
- JAGUAR HEALTH, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$9.62M.
- JAGUAR HEALTH, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$53.94M.
- JAGUAR HEALTH, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$38.31M.
- JAGUAR HEALTH, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$41.27M.
- JAGUAR HEALTH, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$48.13M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.70M 10-Q · filed 2026-08-19 | -$20.12M 10-Q · filed 2026-08-19 | -$43.32M derived: sum of 3 quarters · filed 2026-08-19 | -$52.94M derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | -$7.42M 10-Q · filed 2026-05-20 | -$30.62M derived: sum of 2 quarters · filed 2026-05-20 | -$40.24M derived: sum of 3 quarters · filed 2026-05-20 | -$50.67M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | -$23.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$32.82M derived: sum of 2 quarters · filed 2026-04-07 | -$43.24M derived: sum of 3 quarters · filed 2026-08-19 | -$53.94M 10-K · filed 2026-04-07 |
| 2025-09-30 | -$9.62M 10-Q · filed 2025-11-14 | -$20.05M derived: sum of 2 quarters · filed 2026-08-19 | -$30.75M 10-Q · filed 2025-11-14 | -$40.45M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | -$10.43M 10-Q · filed 2026-08-19 | -$21.12M 10-Q · filed 2026-08-19 | -$30.82M derived: sum of 3 quarters · filed 2026-08-19 | -$40.82M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$10.70M 10-Q · filed 2026-05-20 | -$20.40M derived: sum of 2 quarters · filed 2026-05-20 | -$30.40M derived: sum of 3 quarters · filed 2026-05-20 | -$39.97M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | -$9.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$19.70M derived: sum of 2 quarters · filed 2026-04-07 | -$29.27M derived: sum of 3 quarters · filed 2026-04-07 | -$38.31M 10-K · filed 2026-04-07 |
| 2024-09-30 | -$10.00M 10-Q · filed 2025-11-14 | -$19.57M derived: sum of 2 quarters · filed 2025-11-14 | -$28.61M 10-Q · filed 2025-11-14 | -$37.63M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$9.57M 10-Q · filed 2025-08-14 | -$18.61M 10-Q · filed 2025-08-14 | -$27.64M derived: sum of 3 quarters · filed 2025-08-14 | -$35.49M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$9.04M 10-Q · filed 2025-05-15 | -$18.06M derived: sum of 2 quarters · filed 2025-05-15 | -$25.91M derived: sum of 3 quarters · filed 2025-05-15 | -$37.90M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$9.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$16.88M derived: sum of 2 quarters · filed 2025-03-31 | -$28.87M derived: sum of 3 quarters · filed 2025-03-31 | -$41.27M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$7.85M 10-Q · filed 2024-11-13 | -$19.84M derived: sum of 2 quarters · filed 2024-11-13 | -$32.25M 10-Q · filed 2024-11-13 | -$40.51M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$11.99M 10-Q · filed 2024-08-13 | -$24.39M 10-Q · filed 2024-08-13 | -$32.66M derived: sum of 3 quarters · filed 2024-08-13 | -$45.18M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$12.41M 10-Q · filed 2024-05-14 | -$20.67M derived: sum of 2 quarters · filed 2024-05-14 | -$33.19M derived: sum of 3 quarters · filed 2024-05-14 | -$42.55M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$20.78M derived: sum of 2 quarters · filed 2024-04-01 | -$30.15M derived: sum of 3 quarters · filed 2024-04-01 | -$48.13M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$12.52M 10-Q · filed 2023-11-14 | -$21.89M derived: sum of 2 quarters · filed 2023-11-14 | -$39.87M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$9.37M 10-Q · filed 2023-08-14 | -$27.35M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$17.99M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |